Researchers Announce Important Research on Doxagliptin Diabetes Remission

Shanghai, September 26, 2021/PRNewswire/ - Hua Medicine (the "Company", Hong Kong Stock Exchange stock code: 2552.

The DREAM study is an observational clinical study initiated by some researchers who participated in the SEED study (seeding study, also known as HMM0301), non-pharmacological intervention

The DREAM study was carried out in 5 research centers in China with a total of 69 patients

Professor Ma Jianhua said: “As a brand new glucokinase activator drug, doxagliptin can effectively improve early insulin secretion, improve β-cell function and insulin resistance

In this CBIIC, in addition to the DREAM research results, Dr.

Dr.

Notes:

[1] Calculated using survival analysis

About Dougliptin

Dorzagliatin (dorzagliatin) is the world's first dual-acting glucokinase activator under research, which aims to control the development of progressive degenerative diseases of diabetes by restoring blood glucose homeostasis in patients with type 2 diabetes

About Hualing

Hua Medicine is a biotechnology company based in China that develops global original and innovative drugs for the unmet clinical needs of patients with diabetes worldwide

About the DREAM study

The DREAM study is an observational clinical study of non-pharmacological intervention initiated by some investigators participating in the SEED study (seeding study, also known as HMM0301) to evaluate the effect of dopagliflozin on newly diagnosed untreated hypoglycemic drugs Efficacy for patients with type 2 diabetes

Source: Hua Medicine